- Home
- HEQ vs OBIO Comparison
HEQ vs OBIO Comparison
Compare HEQ & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- OBIO
- Stock Information
- Founded
- HEQ 2011
- OBIO 2017
- Country
- HEQ United States
- OBIO United States
- Employees
- HEQ N/A
- OBIO N/A
- Industry
- HEQ Investment Managers
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- HEQ Finance
- OBIO Health Care
- Exchange
- HEQ Nasdaq
- OBIO Nasdaq
- Market Cap
- HEQ 127.8M
- OBIO 118.8M
- IPO Year
- HEQ N/A
- OBIO N/A
- Fundamental
- Price
- HEQ $10.63
- OBIO $3.29
- Analyst Decision
- HEQ
- OBIO Strong Buy
- Analyst Count
- HEQ 0
- OBIO 5
- Target Price
- HEQ N/A
- OBIO $14.20
- AVG Volume (30 Days)
- HEQ 43.1K
- OBIO 303.1K
- Earning Date
- HEQ 01-01-0001
- OBIO 08-11-2025
- Dividend Yield
- HEQ 9.78%
- OBIO N/A
- EPS Growth
- HEQ N/A
- OBIO N/A
- EPS
- HEQ N/A
- OBIO N/A
- Revenue
- HEQ N/A
- OBIO $2,886,000.00
- Revenue This Year
- HEQ N/A
- OBIO $20.47
- Revenue Next Year
- HEQ N/A
- OBIO $11.45
- P/E Ratio
- HEQ N/A
- OBIO N/A
- Revenue Growth
- HEQ N/A
- OBIO 30.23
- 52 Week Low
- HEQ $9.08
- OBIO $2.37
- 52 Week High
- HEQ $11.84
- OBIO $8.30
- Technical
- Relative Strength Index (RSI)
- HEQ 55.40
- OBIO 60.31
- Support Level
- HEQ $10.45
- OBIO $3.05
- Resistance Level
- HEQ $10.68
- OBIO $3.24
- Average True Range (ATR)
- HEQ 0.07
- OBIO 0.16
- MACD
- HEQ 0.00
- OBIO 0.03
- Stochastic Oscillator
- HEQ 73.68
- OBIO 93.75
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.